SoftBank and Tempus AI launch a joint venture to bring AI-informed treatment recommendations to Japan.

SoftBank Group and Tempus AI have launched a joint venture, aiming to use artificial intelligence (AI) to analyze personal medical data, offering treatment recommendations. SoftBank invested $200 million in Tempus in April, prior to its Nasdaq listing in June. The joint venture hopes to bring AI-informed treatment recommendations and clinical trial recommendations to Japan, making it the only healthcare market outside the US to offer such services.

June 27, 2024
11 Articles